



# Cancer Research

OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH



July 1, 1993  
Volume 53 • Number 13  
PP. 2937-3215  
ISSN 0008-5472 • CNREA 8

# CELL SIGNALLING AND CANCER TREATMENT

Sponsored by:  
**American Association for Cancer Research**  
**European Organisation for Research and Treatment of Cancer**  
**(Pharmacokinetics and Metabolism Group)**  
**British Association for Cancer Research**

December 5-9, 1993

El San Juan Hotel, San Juan, Puerto Rico



## CONFERENCE CHAIRPERSONS

**Garth Powis / Tucson, AZ**

**Paul Workman / Macclesfield, England**

## PROGRAM COMMITTEE

**Sara A. Courtneidge / Heidelberg, Germany**    **Katherine A. Kennedy / Washington, DC**

**Hans H. Grunicke / Innsbruck, Austria**    **John S. Lazo / Pittsburgh, PA**

**John A. Hickman / Manchester, England**    **Thomas R. Tritton / Burlington, VT**

## SCIENTIFIC PROGRAM

### Introduction

**Garth Powis / Tucson, AZ**  
**Allen I. Oliff / West Point, PA**

### Tyrosine Kinases and Inhibitors

**Lewis T. Williams / San Francisco, CA**  
**Alexander Levitzki / Jerusalem, Israel**  
**Alex Matter / Basel, Switzerland**

### Serine/Threonine Kinases and Inhibitors

**Peter J. Parker / London, England**  
**Hans H. Grunicke / Innsbruck, Austria**

### GTP Binding Proteins

**Alan K. Hall / London, England**  
**Frank McCormick / Richmond, CA**  
**Jay Gibbs / West Point, PA**

### Domain Binding and Inhibition

**Sara A. Courtneidge / Heidelberg, Germany**

### Lipid Signalling

**Lewis C. Cantley / Boston, MA**  
**Alan P. Kozikowski / Rochester, MN**  
**Paul Workman / Macclesfield, England**  
**Garth Powis / Tucson, AZ**

### Modulation of Signalling in Combination Chemotherapy

**Thomas R. Tritton / Burlington, VT**  
**John S. Lazo / Pittsburgh, PA**  
**Stephen B. Howell / La Jolla, CA**

### Signalling and the Cell Cycle

**Laurent Meijer / Roscoff, France**  
**Caroline Dive / Manchester, England**  
**Michael J. Morin / Groton, CT**  
**Doris L. Slate / Palo Alto, CA**  
**Adrian L. Harris / Oxford, England**

### Gene Targeting

**Stanley T. Crooke / Carlsbad, CA**  
**Michael E. Hogan / Houston, TX**

### Summary

**Paul Workman / Macclesfield, England**

*Applicants are encouraged to submit abstracts  
for poster presentation.*

### Information and Application Forms


American Association for Cancer Research  
Public Ledger Building  
620 Chestnut Street, Suite 816  
Philadelphia, PA 19106-3483  
215-440-9300    215-440-9313 (FAX)

---

**Application Deadline: September 7, 1993**

# COVER LEGEND

---



This issue's cover of *Cancer Research* honors Dr. Irwin H. Krakoff and his significant contributions to the field of medical oncology. During his forty-year career, Dr. Krakoff has been at the forefront of a select group of clinician-scientists who nurtured the new discipline, established safe methods for the testing of new and often toxic agents, and championed the synthesis of studies from the bench and bedside in understanding the role of chemotherapy in the treatment of cancer. Medical oncologists today approach the care of cancer patients with a chemotherapeutic armamentarium derived in large part from the achievements of Dr. Krakoff and the research teams of which he was a part. In addition to participating in and guiding the clinical trials which launched many new agents, Dr. Krakoff's interest and expertise in the pharmacological evaluation of antineoplastic compounds led to a parallel series of laboratory studies which explored crucial questions regarding the pharmacokinetic and metabolic dispositions of these new agents. He made important contributions to our understanding of purine metabolism in patients with leukemia. His studies established the role of allopurinol in preventing urate nephropathy, which had been a major complication in the treatment of leukemia and lymphoma. In 1965, he was awarded the Alfred P. Sloan Award for Cancer Research, and in May 1993 the Karnofsky Award of the American Society of Clinical Oncology.

After completing medical school at Ohio State in 1947, and performing his internship and residencies in Cleveland and Boston, in 1953 Dr. Krakoff joined the Memorial-Sloan Kettering group, directed by Drs. Joseph Burchenal and David Karnofsky. In 1970, his broad involvement in the drug development program led to his appointment as Chief of the Medical Oncology Service of Memorial Hospital and Chief of the Division of Chemotherapy of the Sloan-Kettering Institute, New York, NY (*right*), reflecting his dual commitment to laboratory and clinical investigation. In 1976, he became Director of the Vermont Regional Cancer Center, Burlington, VT (*left*). Under his leadership, this center became a regional resource for coordinating the care of cancer patients between oncologists and local physicians.

In 1983, Dr. Krakoff became Head of the Division of Medicine at the University of Texas M. D. Anderson Cancer Center, Houston, TX (*top center*). During the ten years of his stewardship, the medical program at M. D. Anderson doubled its clinical faculty and markedly expanded its laboratory programs in pharmacology, chemistry, immunology, chemoprevention, and molecular biology. Today, the Division has nearly 200 physician and scientist faculty members and is responsible for the treatment of close to 6000 new patients each year. Its research programs include over 400 active clinical trials, which are supported by more than 20 million dollars of grant and contract funding. These programs are respected for the rigorous data management and reporting systems initiated under Dr. Krakoff's leadership.

However, Dr. Krakoff's most important contributions to the future of cancer therapy and research have been in the area of education. In his role as director of three major oncology programs, Dr. Krakoff not only helped to establish the foundation of the new science but also dedicated himself to the training of the second and third generations of clinical investigators, who are continuing the rigorous trials which lead to further advances in drug therapy. His precept that learning *whether* a chemotherapeutic agent is effective is not as important as determining *why* it is effective has shaped the thinking of hundreds of medical oncology researchers. The field of medical oncology has benefitted immensely from this imprint.

We are indebted to Dr. Waun Ki Hong and the M. D. Anderson Cancer Center staff for providing the photographs and background information.

Sidney Weinhouse